Masitinib (6.0) — Competitive Intelligence Brief

Masitinib (6.0) (Masitinib (6.0)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor. Area: Neurology, Immunology, Oncology.

phase 3 Tyrosine kinase inhibitor c-Kit, PDGF receptor, Lyn kinase Neurology, Immunology, Oncology Small molecule

Target snapshot

Masitinib (6.0) (Masitinib (6.0)) — AB Science. Masitinib is a tyrosine kinase inhibitor that selectively targets c-Kit, PDGF receptor, and Lyn kinase to modulate immune cell activation and reduce inflammatory responses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Masitinib (6.0) TARGET	Masitinib (6.0)	AB Science	phase 3	Tyrosine kinase inhibitor	c-Kit, PDGF receptor, Lyn kinase
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
Cipterbin Combined With Vinorelbine	Cipterbin Combined With Vinorelbine	Zhejiang Cancer Hospital	marketed	Tyrosine kinase inhibitor combined with vinca alkaloid	Multiple tyrosine kinases (cipterbin); tubulin (vinorelbine)
Vizimpro	Dacomitinib	Pfizer Inc.	marketed	Tyrosine kinase inhibitor (TKI); Pan-HER inhibitor	Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3
Nilotinib 300 mg.	Nilotinib 300 mg.	King Abdullah International Medical Research Center	marketed	BCR-ABL tyrosine kinase inhibitor	BCR-ABL
Erlotinib, Pemetrexed	Erlotinib, Pemetrexed	Hunan Province Tumor Hospital	marketed	EGFR tyrosine kinase inhibitor + antifolate antimetabolite	EGFR; thymidylate synthase and folate-dependent enzymes
Lenvatinib + losartan	Lenvatinib + losartan	Second Affiliated Hospital of Xi'an Jiaotong University	marketed	Multi-targeted tyrosine kinase inhibitor + angiotensin II receptor antagonist	FGFR, VEGFR, RET (lenvatinib); AT1 receptor (losartan)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor class)

1. Jiangsu HengRui Medicine Co., Ltd. · 5 drugs in this class
2. Centre Leon Berard · 2 drugs in this class
3. AB Science · 2 drugs in this class
4. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
5. Betta Pharmaceuticals Co., Ltd. · 1 drug in this class
6. Angion Biomedica Corp · 1 drug in this class
7. Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
8. Chang-Ming Huang, Prof. · 1 drug in this class
9. Deciphera Pharmaceuticals, LLC · 1 drug in this class
10. AstraZeneca · 1 drug in this class